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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the feasibility and safety of discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults aged
over 18 years.
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B A C K G R O U N D
Description of the condition
Antidepressant use
Antidepressants can be divided into various classes based on
their slightly diFerent mechanisms of action (see Table 1). They
act, with a few exceptions, by enhancing the transmission of the
chemical messengers dopamine, noradrenaline (norepinephrine),
adrenaline (epinephrine) and serotonin, which are thought to be
involved in mood regulation in the brain. However, the exact
mechanism of action of antidepressants is still not known (Harmer
2017).
The consumption of antidepressants has increased significantly in
most countries since 2000 and continues to rise (OECD 2017). The
highest use per population in the Convention on the Organisation
for Economic Co-operation and Development (OECD) Health
Report is seen in Iceland, Australia, Portugal, UK, Sweden, Canada
and Belgium (OECD 2017). About 12.7% of Belgian adults take
antidepressants daily (RIZIV 2014), with similar rates in the UK
(16%; DHSC 2018), and many other European countries (Gusmão
2013). In the USA the rate is about 12.7% (Pratt 2018), and in
Australia about 16.8% of adults take antidepressants daily (Brett
2017).
Like most prescribed medicines, antidepressants can have side-
eFects and adverse eFects. Very common (more than 10%) adverse
events ('harms') for all antidepressants are sleep disturbance,
sexual dysfunction and gastro-intestinal problems. More serious
rare adverse eFects (0.01% to 0.1%), are higher risk of agitation
and suicide at the beginning of the treatment or when increasing
dosage, gastro-intestinal bleeding, and in older people, low
sodium in the blood with risk of agitation and confusion and an
increased risk of fracture (BCFI/CBIP 2018). Each antidepressant
is also associated with side eFects related to their mechanism
of action. For example, very common side eFects (more than
10%) of tricyclic agents (TCA) are blurred vision, constipation, and
dry mouth due to the anticholinergic properties of TCAs. Other
common problematic anticholinergic eFects (1% to 10%), include
an increased intra-ocular pressure, urinary retention, postural
hypotension, dizziness and a negative impact on cognition in older
people. Patients also commonly report adverse eFects on mood
and emotion, such as feeling emotionally numb and addicted
(Cartwright 2016). Long-term antidepressant use may also impair
patients’ autonomy and increase their dependence on medical
help and medication (Kendrick 2015). Typical antidepressant
withdrawal symptoms or discontinuation symptoms, such as flu-
like symptoms, insomnia, nausea, imbalance or vertigo, sensory
disturbances, and hyperarousal (anxiety and agitation), can
occur when stopping, missing doses or reducing doses of any
antidepressant.
A previous Cochrane Review on antidepressant treatment for
depression in primary care suggested that, for one person to
experience side eFects that led the person to stop taking the
antidepressant drug (i.e. number needed to treat for an additional
harmful outcome (NNTH); Arroll 2009), between 4 and 30 people
needed to be treated with a TCA, and between 20 and 90 people
with selective serotonin reuptake inhibitors (SSRI). In older people,
antidepressants tend to pose a greater risk of adverse events
because of co-existing disease and drug-drug interactions related
to other medications taken regularly (Kok 2017).
Indications of antidepressants
Depressive disorders
The most prevalent condition that warrants the use of
antidepressants in the community and in nursing homes is
depression (Bourgeois 2012; Wong 2016).
According to the Diagnostic and Statistical Manual of Mental
Disorders 5th edition (DSM-V) classification, a major depressive
disorder is defined as a period of at least two weeks during
which there is either depressed mood or the loss of interest or
pleasure in nearly all activities, and also at least four additional
symptoms from the following: changes in appetite, weight, sleep or
psychomotor activity, decreased energy, feelings of worthlessness
or guilt, diFiculty concentrating or thinking or making decisions,
or recurrent thoughts of death or suicidal ideation or suicide plans
or attempts (APA 2013). The symptoms must persist for most of
the day, nearly every day, for at least two consecutive weeks. The
episode must be accompanied by clinically significant distress or
impairment in social, occupational or other important areas of
functioning. A major depressive episode is a period of two weeks
or more, characterised by the symptoms of a major depressive
disorder (APA 2013). Severity of the major depressive disorder
(mild, moderate, severe) must be based on the number of criterion
symptoms, the severity of those symptoms and the extent to which
usual social and working activity is limited and not rely simply on
counting the number of symptoms (APA 2013).
Diagnosing depression can be diFicult due to these broad and
subjective diagnostic criteria and lack of a reliable and valid test for
depression in primary care.
An untreated depressive episode typically lasts about four to
six months on average (NICE 2016; Solomon 1997). Although
approximately half of the people who become depressed will
only have a single episode of depression in their lifetimes,
approximately 50% will have multiple episodes or persistent
depressive disorders (Eaton 2008; MoFit 2010). Recurrence is
common; there is a 50% chance of recurrence aOer a first episode,
rising to 70% and 90% aOer a second or third episode respectively
(NICE 2016). Therefore it is recommended that treatment should
focus not only on improving symptoms of the acute episode, but
also on prevention of relapse (return of symptoms of the original
depressive episode) and recurrence (development of a subsequent
episode) (NICE 2016).
There are three distinct phases in the treatment of depressive
disorder: acute, continuation and maintenance treatment (APA
2010). Acute therapy is the treatment phase focused on treating
the patient to remission and typically lasts six to 12 weeks. The
continuation phase is the treatment phase during the first six
months aOer having achieved remission and aims to prevent
recurrence of the original depressive episode. The maintenance
treatment is treatment to prevent recurrence of depression or a
new depressive episode aOer remission (Frank 1991).
Acute treatment
Antidepressants have been shown to be eFicacious in adults,
compared to placebo, in the acute treatment of major depressive
disorder in the short term, although the eFect is small (Cipriani
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2018). In a previous Cochrane Review, authors found that, for
depression in primary care, between 7 and 8 people needed
to be treated with a SSRI and between 7 and 16 people with
a TCA for 1 person to experience improvement of depression
due to the antidepressant use (i.e. number needed to treat for
an additional beneficial outcome (NNTB); Arroll 2009). However,
there is also increasing criticism about the lack of evidence for
eFectiveness of antidepressants in the acute treatment of mild to
moderate depressive disorders, due to important limitations of the
available evidence base (McCormak 2018; Munkholm 2019). There
is insuFicient evidence to support or to contest the eFicacy of
antidepressant medication for subthreshold and mild depressive
disorder (Cameron 2014).
Continuation and maintenance treatment
Evidence suggests that continuation of antidepressant treatment
is eFective as it reduces the risk of relapse and recurrence
by 50% to 70% (Geddes 2003; Glue 2010; Kaymaz 2008; NICE
2016), although almost all trials on which this conclusion was
based were conducted in secondary care and are probably not
representative of primary-care patients (Aroll 2017). The evidence
for treatment durations of more than nine months is relatively
limited, with a lack of long-term trials in which participants
were randomised six months aOer remission to determine the
eFects of treatment aOer this time (Kaymaz 2008). A previous
Cochrane Review on continuation and maintenance trials for
older people with depressive disorders found that the long-term
benefits and harms of continuing antidepressant medication in
the prevention of recurrence of depression are not clear and
no firm treatment recommendations can be made (Wilkinson
2016). Moreover, evidence showed no association between relapse
rates and duration of treatment (Geddes 2003), and there was
no evidence to justify the defined clinical distinction between
continuation treatment (six to nine months) and maintenance
treatment (for two years or longer; Kaymaz 2008). Another
Cochrane Review of trials in people with persistent depressive
disorder found that it is uncertain whether continued or maintained
pharmacotherapy (or both) with antidepressant agents is a robust
treatment for preventing relapse and recurrence due to moderate
or high risk of bias (Machmutow 2019).
Guidelines have underlined the importance of giving
antidepressants for a suFicient period of time. The recommended
duration of continuation treatment varies from four months to
12 months in depression guidelines aOer remission (APA 2010;
CANMAT 2016; Declercq 2017; NHG 2012; NICE 2016; WHO 2017).
Continuation treatment should be continued for at least two
years aOer remission in those at high risk of relapse (APA 2010;
CANMAT 2016; Declercq 2017; NHG 2012; NICE 2016; WHO 2017),
which is defined as patients having two or more episodes, residual
symptoms and severe previous episodes, as these factors are
related to a poorer prognosis overall (Geddes 2003). People
with depression on long-term maintenance treatment should
be regularly re-evaluated. Due to the lack of evidence for the
optimal duration of continuation and maintenance treatment,
most guidelines are based on expert opinion.
Anxiety disorders
AOer depression, anxiety disorders (e.g. generalised anxiety
disorder, panic disorders or any other anxiety disorder) are
the most frequent indication for which antidepressants are
prescribed (Wong 2016). Cognitive behavioural therapy (CBT) and
antidepressants are both first-line options for the treatment of
anxiety disorders with proven eFectiveness (Batelaan 2017; NICE
2011). Antidepressant treatment duration of up to one year results
in lower relapse rates among responders compared with treatment
discontinuation in anxiety disorders, irrespective of type of anxiety
disorder (Batelaan 2017). However, long-term trials are scarce.
International guidelines are therefore consensus-based and advise
continuation of treatment for variable durations (6 to 24 months;
Baldwin 2014; NICE 2011).
Long-term antidepressant use
Long-term antidepressant prescription is driving much of the rise
in antidepressant use (Brett 2017; Kjosavik 2016; Mars 2017). In the
Netherlands, approximately 30% of people taking antidepressants
take them for more than one year (Meijer 2004). In the UK, nearly
half of the antidepressant users (8% of the total population)
have been taking them for more than two years (Johnson 2012),
and in the USA half of the antidepressant users (7% of the total
population) have been taking them for more than five years
(Mojtabi 2014). In Australia, the average duration of treatment
with antidepressants is about four years (Kjosavik 2016). High
antidepressant use has also been reported in people living in
nursing homes. About 40% of Belgian nursing-home residents take
antidepressants daily (Bourgeois 2012), with similar rates seen in
other European countries (Janus 2016), and the USA (Karkare 2011).
Antidepressants that, despite initially being appropriate, are not
discontinued aOer the recommended treatment period, can lead
to long-term unnecessary medication. A recent trial described
inappropriate duration of antidepressants, for example, for longer
than needed, as “legacy prescribing” (Mangin 2018).
Trials suggest that the motives and barriers of patients and
physicians to continue or discontinue antidepressants are
numerous and complex (Bosman 2016; Maund 2018). A recent
review synthesised 49 barriers and facilitators in nine themes
related to patients' perspectives: psychological and physical
capabilities, perception of antidepressants, fears of relapse and/
or recurrence, intrinsic motivators and goals, the physician as
a navigator to maintenance or discontinuation, perceived cause
of depression, aspects of information that support decision-
making, significant others (a help or a hindrance) and support
from other health professionals (Maund 2018). A key barrier
was the patient's belief that the physician was responsible
for initiating discussions about discontinuation. Other identified
barriers are related to the availability of supportive non-
pharmacological guidance during discontinuation, the personal
circumstances of the patient and the underlying considerations and
knowledge of the patients and physicians (Bosman 2016). Patients
continued using antidepressants because of fear of relapse, a
perceived biological cause for their depressive symptoms and
their experience of improved functioning. It was also easier for
physicians to prescribe antidepressants for depression as they are
more accessible than psychological treatment. In one open, single-
arm trial with older patients from nursing homes, resistance to
discontinuing antidepressants largely came from the relatives and
not the carers of the older individuals (Lindstrom 2007).
Discontinuing antidepressant treatment can be complicated by
the potential for patients to experience withdrawal symptoms.
Discontinuation symptoms refer to physical and psychological
Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults (Protocol)
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symptoms that occur when stopping, missing doses or reducing
doses (even with gradual tapering) of any antidepressant
(APA 2013). Symptoms generally begin two to four days aOer
abrupt discontinuation of antidepressants that had been taken
continuously for at least one month (APA 2013). Late onset or longer
persistence, lasting weeks to months, has also occurred (Davies
2019). Antidepressant withdrawal reactions are widespread. A
recent review suggests incidence rates from 27% to 86%, with an
average incidence of 56%, and with up to half of those experiencing
withdrawal symptoms having severe reactions (Davies 2019).
Withdrawal symptoms are oOen very similar to symptoms of
relapse or recurrence and may sometimes be misleading and
misdiagnosed as depressive recurrence, leading to unnecessary
continuation of antidepressant use. If the same or a similar drug is
restarted, the withdrawal symptoms will usually resolve fully within
one to three days and subsequently the antidepressant can be
withdrawn more cautiously (Haddad 2007). Withdrawal symptoms
can be distinguished from relapse of the original disorder by their
rapid onset aOer stopping antidepressants. Whereas relapse is
uncommon in the first weeks aOer stopping, the rapid response
aOer reintroducing the original antidepressant and the presence of
somatic and psychological withdrawal symptoms is diFerent from
the original depressive or anxiety disorder (Haddad 2007; Horowitz
2019). However, many withdrawal variations aOer discontinuation
are possible including late onset of the symptoms (sometimes
aOer several months) making misdiagnosis of withdrawal possible.
Additionally, one of the more serious withdrawal reactions can
be anxiety symptoms. As antidepressants have been widely
prescribed for anxiety disorders, it is a challenge to distinguish
withdrawal from relapse of the original anxiety disorder (Davies
2019; Fava 2015). The risk of discontinuation symptoms is higher
with antidepressants with a shorter half-life (the time taken for
blood concentration to be reduced by 50%), where high doses have
been prescribed, and in cases where rapid tapering occurs (APA
2013). The risk also appears to be higher for those who have taken
antidepressants for eight weeks or longer (APA 2013).
Description of the intervention
Guidelines recommend discontinuation of antidepressant drugs
aOer successful treatment (NICE 2016). Abrupt discontinuation of
antidepressants may lead to temporary withdrawal symptoms.
A common strategy is to taper (gradually reduce the dose)
antidepressants over weeks to reduce the risk of withdrawal
symptoms (NICE 2016). The National Institute for Health and
Care Excellence (NICE) recommends gradually reducing the
antidepressant dose every one to two weeks, over a four-
week period, although some people may require longer periods,
particularly with drugs with a shorter half-life (such as paroxetine
and venlafaxine; NICE 2016). However, there is a lack of evidence
regarding strategies for discontinuation of antidepressants and
the optimal method of stopping antidepressants is currently
unknown; withdrawal symptoms can always occur despite a slow
taper approach (Horowitz 2019). It is important that patients are
informed at the time of initiation of an antidepressant of the
intention to stop treatment when their condition has improved, and
that this may present a risk of withdrawal symptoms.
Psychological interventions in combination with discontinuation of
antidepressants could support the process of discontinuation.
• CBT focuses on the cognitive content of negative thinking
and on learning a repertoire of coping skills appropriate to
the target thoughts, beliefs or problem areas (NICE 2016).
Patients work with a therapist, either face to face or via
telecommunication technologies (online therapy) and CBT can
be delivered individually or in group. A meta-analysis on the
sequential integration of pharmacotherapy and psychotherapy
in major depressive disorder suggests that participants receiving
CBT aOer antidepressant discontinuation were significantly
less likely to relapse compared to continued pharmacotherapy
(Guidi 2016). A recent review of two trials found that the risk
of relapse or recurrence was lower with CBT plus tapering
compared to clinical management plus tapering aOer two years
(Maund 2019).
• Mindfulness-based cognitive therapy (MB-CT) is a group-based
clinical intervention programme designed to reduce relapse or
recurrence of major depressive disorder by means of systematic
training in mindfulness meditation combined with cognitive-
behavioral methods (Piet 2011). MB-CT is a manualised, group-
based skills training programme intended to teach people skills
to deal with their negative feelings and thoughts as a part of their
lives through becoming aware of negative cognitive patterns
(Piet 2011). A meta-analysis of six trials showed that MB-CT
reduces the 12-month relapse/recurrence risk compared with
usual care or placebo, with a relative risk reduction of 43%, in
patients with a history of three or more episodes of depression
(Huijbers 2016; Piet 2011). A recent systematic review about
the eFectiveness of interventions to manage antidepressant
discontinuation found in two trials that relapse or recurrence
rates were similar for MB-CT in combination with tapering and
for maintenance antidepressants (Maund 2019).
• Low-intensity psychosocial interventions may use simple
approaches that are less complex to undertake than CBT or MB-
CT. Contact with people is generally briefer than in other forms
of therapy and can be delivered by para-professionals or peer
supporters using non-traditional methods such as telephone
or the internet. There is no clear definition of low-intensity
psychosocial intervention for depression or anxiety in the
literature (NICE 2016;Rodgers 2012). The NICE guideline found
evidence on three main forms of low-intensity psychosocial
interventions in the acute treatment of depression: individual,
guided self-help based on the principles of CBT, computerised
CBT and a structured group physical activity programme (NICE
2016). However, low-intensity psychosocial interventions can
also be used as relapse prevention. One trial suggested that the
combination of a self-help intervention with a self-help book
and weekly guidance in primary care could prevent relapse of
depression in participants with recurrent depressive episodes
(Biesheuvel 2015). Antidepressant discontinuation can also
be supported by a letter with patient-specific discontinuation
advice (Eveleigh 2017). This was based on previous evidence
where a letter with discontinuation advice was sent to long-term
benzodiazepine users in family practice followed by a follow-up
consultation (Gorgels 2005). Online low-intensity interventions
could oFer online modules and information to patients
and practitioners to support antidepressant discontinuation
(ISRCTN15036829).
These findings suggest that cognitive therapy and MB-CT
in combination with discontinuation of antidepressants are
potential alternatives to antidepressants for preventing relapse or
recurrence. However, CBT and MB-CT are resource intensive and
Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults (Protocol)
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access to these psychological interventions is oOen limited. Low-
intensity psychosocial interventions have the potential to reach
more people.
Pharmacological treatment with benzodiazepines is suggested, by
some experts, as short-term treatment to counteract insomnia
associated with withdrawal (Haddad 2007; NHG 2018). However,
benzodiazepines may contribute to a risk of dependence, especially
in older people, and prescribing long-term benzodiazepines is
not appropriate as a substitute for unnecessary antidepressant
treatment (Pottie 2018; Wilson 2010).
How the intervention might work
Discontinuation of antidepressants may decrease the risk of
adverse events, risk of drug-drug interactions and minimise the
number of medicines whilst making no diFerence in depressive
and anxiety symptoms. However, discontinuation might also cause
withdrawal symptoms and recurrence or worsening of the original
depressive or anxiety symptoms, which contributes to unsuccessful
discontinuation.
The exact therapeutic mechanism of antidepressants is not
known (Pringle 2011). Most antidepressants seem to increase the
concentrations of monamine neurotransmitters in the synaptic
cleO (Berton 2006). The eFect of most antidepressants fully
develops aOer some weeks, indicating that neurophysiological
changes of brain tissue (e.g. changes in sensitivity and frequency
of receptors) occurring in the presence of a constant level of
active ingredients, are necessary for improvement in depressive
symptoms (Machmutow 2019). Depending on the active ingredient,
antidepressants can have mood-enhancing, anxiolytic or sedative
eFects and are able to increase or decrease inner drive
(Machmutow 2019). The rationale for continuing antidepressant
treatment aOer clinical recovery is that it will sustain the regulation
of the monoamine activity (Wilkinson 2016). However, suggesting
that a single biochemical deficiency is the cause of depression and
that antidepressants work by correcting chemical deficiency is too
simplistic (Andrews 2015).
Various explanations for the mechanism of withdrawal symptoms
when stopping antidepressants have been proposed (Fava 2015;
Horowitz 2019). Daily drug treatment activates receptors, which in
turn can aFect the availability of several neurotransmitters that can
lead to many downstream physiological consequences. When drug
treatment abruptly stops, the homeostatic equilibrium is disturbed
and the body’s adaptive changes take time to recalibrate, resulting
in a period of possible withdrawal symptoms (Fava 2015; Horowitz
2019). The neurobiological mechanism of tapering is based on the
rationale that biological systems will have more time to adapt
to reductions in available ligand, thus reducing the intensity of
withdrawal symptoms (Fava 2015).
Additional non-pharmacology treatments can support
discontinuation of antidepressants. CBT approaches focus on
dysfunctional thoughts, feelings and behaviour, and learning skills
(NICE 2016). MB-CT was specifically developed to reduce relapse
and recurrence in depression (Piet 2011; Segal 2002). However,
the exact mechanisms of preventing relapse and recurrence of
psychological interventions remain unclear (Beshai 2011).
Symptoms of discontinuation of antidepressants could be treated
by a short treatment of benzodiazepines. Benzodiazepines act
through binding at, and enhancing the eFect of gamma-
aminobutyric acid (GABA) receptors (Ma 2019). Enhancement
of the eFect of GABA on this receptor results in sedative,
anxiolytic, hypnotic and muscle relaxant eFects, thus reducing
discontinuation symptoms.
It is important that practitioners should share decision making
about discontinuation strategies with the patient and their relatives
for successful antidepressant discontinuation.
Why it is important to do this review
Antidepressant use can be accompanied by minor adverse events
as well as serious adverse events. While recommendations have
underlined the importance of giving antidepressants for a suFicient
length of time, there is increasing concern about the overuse of
antidepressants (i.e. longer than recommended) for depression,
but also for a growing number of other conditions (Kjosavik
2016; Wong 2017). Reviews suggest that 30% to 50% of long-term
antidepressant prescriptions had no evidence-based indication
supporting their use and that users could try to stop treatment
(Ambresin 2015; Cruickshank 2008; Piek 2010).
The eFectiveness of interventions aimed at discontinuation of
long-term antidepressant use is unknown. Most antidepressant
guidelines recommend a slow taper approach over several weeks
(APA 2010; CANMAT 2016; NICE 2016). NICE recommendations
for stopping antidepressants are to gradually reduce the dose,
normally over a four-week period (NICE 2016). Overall, there is
a lack of strong evidence supporting how best to discontinue
unnecessary antidepressant use (Horowitz 2019).
Therefore we will perform a systematic review of discontinuation in
participants using antidepressants for longer than recommended,
defined as use of at least six months or more.
A systematic review of discontinuation trials on long-term
antidepressants will assist clinicians and patients in shared
decision making for an evidence-based choice for appropriate
antidepressant prescribing and will have an impact on the
guidelines for depressive and anxiety disorder.
O B J E C T I V E S
To assess the feasibility and safety of discontinuation of long-term
antidepressant use for depressive and anxiety disorders in adults
aged over 18 years.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), published and
unpublished trials, open-label and double-blinded trials, as well
as cluster-RCTs. We will include both placebo-controlled and non-
placebo-controlled trials. We will exclude cross-over trials.
Types of participants
Participant characteristics
Trial participants, aged 18 years and older, using long-term
antidepressants, prescribed for depressive or anxiety disorder.
Long-term is defined as use of at least six months of any
Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults (Protocol)
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antidepressant treatment. Diagnosis of depressive and anxiety
disorder is defined by trial authors. We will include trials with any
from the following classes of antidepressants.
• Selective serotonin reuptake inhibitors (SSRIs)
• Serotonin-noradrenaline antidepressants (SNRIs)
• Noradrenaline reuptake inhibitors (NARIs)
• Tricyclic antidepressants (TCAs)
• Noradrenaline-dopamine reuptake inhibitors (NDRIs)
• Monoamine oxidase inhibitors (MAOIs)
• Other antidepressants:
* melatonergic antidepressants
* noradrenergic and specific serotonergic antidepressants
(NASSAs)
* serotonin antagonist and reuptake inhibitors
* multimodal serotonin reuptake inhibitor and receptor
blocker
* St. John's Wort (Hypericum perforatum) and other natural
products
We will not place restrictions on the dose of antidepressant
treatment.
In this review, we will use the term 'depression' to refer to the DSM-
V diagnosis of major depressive disorder.
Setting
We will include trials in a range of settings (e.g. primary care,
outpatient psychiatric hospital, nursing home).
Exclusion criteria
We will exclude trials that include participants with, or with
a history of bipolar disorder, obsessive compulsive disorder or
psychosis.
We will exclude discontinuation trials in the context of
electroconvulsive therapy or hospital admission.
We will exclude discontinuation trials if participants were not
treated in line with the recommended duration of treatment.
Therefore, we will exclude discontinuation trials if participants have
received less than six months of antidepressant treatment.
Types of interventions
We will include trials that compare discontinuation to continued
antidepressant use or usual care.
Experimental Intervention
We will define discontinuation of antidepressants as one or more of
the following interventions.
• Abrupt discontinuation: abruptly discontinuing an
antidepressant either using placebo or no medication
• Tapering: gradually reducing the dose until complete
discontinuation of antidepressant use either using placebo or
no medication
• Combined intervention (high intensity): one or more
high-intensity psychological interventions combined with
discontinuation of antidepressants, either abruptly or tapering.
Psychological interventions must have been based on a
scientific theory, with at least one contact between therapist
and participant, either face to face or via telecommunication
technologies. The intervention must have considered the
personal needs of the participants or a group of participants.
We will consider CBT, MB-CT, behaviour therapy, interpersonal
therapy (IPT), behaviour modification/therapy or any other
psychologically orientated interventions.
• Combined intervention (low intensity): one or more
low-intensity psychosocial interventions combined with
discontinuation of antidepressants, either abruptly or tapering.
Low-intensity interventions are simple approaches that are less
complex to undertake than formal high-intensity psychological
interventions; contact with people is generally briefer than
in other forms of therapy and can be delivered by para-
professionals or peer supporters using non-traditional methods
such as telephone or the internet. We will consider individual,
guided self-help based on the principles of CBT, computerised
CBT, a structured group physical activity programme or any
other low-intensity psychosocial interventions.
• Discontinuation, either abruptly or tapering, with
pharmacological treatment to counteract antidepressant
withdrawal symptoms, for example, benzodiazepines as short-
term treatment to support discontinuation and to counteract
insomnia associated with discontinuation.
Comparator intervention
• Continuation of antidepressant use
• Usual care or treatment as usual, mostly continuation of
antidepressant use, according to clinical judgement
Co-interventions of any kind or any kind of non-pharmacological
treatment for discontinuation in the intervention and the control
groups are allowed.
Types of outcome measures
We will include trials that meet the above inclusion criteria
regardless of whether they report on the following outcomes.
We will use the definitions of diagnosis, response, relapse
and recurrence as defined by trial authors. Appendix 1 lists
abbreviations of the measuring instruments used in this review.
Primary outcomes
1. Successful discontinuation rate: the proportion (%) of
participants who successfully discontinued antidepressants at
the end of the trial. We define successful discontinuation as:
a. no antidepressant use; and
b. absence of depressive or anxiety symptoms or diagnosis, or
both; and
c. no drop-out before the end of the trial.
2. Relapse rate: the proportion (%) of participants who did not
successfully discontinue antidepressants at the end of the
Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults (Protocol)
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trial due to relapse or recurrence of depressive and/or anxiety
symptoms and/or diagnosis. We define relapse rate as:
a. relapse of depressive and/or anxiety symptoms and/or
diagnosis aOer continuation; or
b. relapse of antidepressant use aOer discontinuation due to
presence of depressive and/or anxiety symptoms and/or
diagnosis; or
c. relapse of depressive and/or anxiety symptoms aOer
discontinuation; or
d. dropout from the trial due to relapse to depressive and/or
anxiety symptoms and/or diagnosis.
3. The presence of discontinuation symptoms (measured by
Discontinuation-Emergent Signs and Symptoms (DESS) Scale
(Rosenbaum 1988), symptoms assessment form, unified
Parkinson disease rating scale or any relevant instrument).
4. Any adverse events attributable to the continuation of
antidepressant use.
Secondary outcomes
1. Depressive symptoms and anxiety symptoms as measured on
a scale (measured by the Hamilton Depression Rating Scale
(HDRS; Hamilton 1960), the Montgomery-Åsberg Depression
Rating Scale (MADRS; Montgomery 1997), the Beck Depression
Inventory (BDI; Beck 1961), the Inventory of Depressive
Symptomatology (IDS; Rush 2000), the Patient Health
Questionnaire (PHQ; Spitzer 1999), Beck Anxiety Inventory (BAI;
Beck 1993), the Hamilton Anxiety Scale (HAM-A) for General
Anxiety Disorder (Hamilton 1959; Maier 1988), General Anxiety
Disorder (GAD-7; Spitzer 2006), the Panic and Agoraphobia Scale
(PAS; Bandelow 1992), or any other instrument)
2. Time to relapse aOer randomisation (measured in weeks)
3. Quality of life of participants (measured by Short Form 36 (SF-36;
Ware 1992), Short Form 12 (SF-12; Gandek 1998), or any other
instrument)
4. Social and occupational functioning (measured by Global
Assessment of Function Scores (GAFS; APA 2000), Occupational
Functioning Scale (OFS; Hannula 2006), or any other instrument)
5. Severity of a patient's illness assessed by a health professional
(clinical global impression measured by Clinical Global
Impression Change scale (CGI-C; Busner 2007), or any other
instrument)
Timing of outcome assessment
We will analyse the eFects of discontinuation over the short term
(trials with follow-up of four weeks or less), over the titration period
used in the trial, over the medium term (trials with follow-up from
four weeks to six months) and long term (trials with follow-up of six
months or more aOer discontinuation). We will prioritise outcomes
over the medium term (from four weeks to six months) and long
term (follow-up 6 months or more).
Hierarchy of outcome measures
We will consider the outcome measurements at the predefined
endpoint of the trial.
If trials use diFerent outcome measures, we will include data as per
the following rules: in case of available data from both observer-
rating scales and self-report questionnaires, we will prioritise data
from observer-rating scales. We will use the DSM-V definitions for
depressive disorder and anxiety disorder (APA 2013), relapse and
recurrence definitions of Frank 1991, HAM-D scale for depressive
symptoms and the HAM-A for anxiety symptoms. In case of several
outcome measures of the same hierarchy level used in one trial, we
will select the outcome measure most frequently used across all
trials. In case of several outcome measures of the same hierarchy
level and the same availability across trials, we will randomly select
the outcome measure. If trials do not report the HAM-D or HAM-
A, where applicable we will select the outcome measure most
frequently used across all trials.
Search methods for identification of studies
Cochrane Common Mental Disorders Controlled Trials Register
(CCMD-CTR)
Cochrane Common Mental Disorders maintains a specialised
register of RCTs, the CCMD-CTR. This register contains over 40,000
reference records (reports of RCTs) for anxiety and depressive
disorders, bipolar disorder, eating disorders, self-harm and other
mental disorders within the scope of this Group. The CCMD-
CTR is a partially trials-based register with more than 50%
of the reference records tagged to around 12,600 individually
PICO-coded trial records. Reports of trials for inclusion in the
register are collated from (weekly) generic searches of MEDLINE
(1950-), Embase (1974-) and PsycINFO (1967-), quarterly searches
of the Cochrane Central Register of Controlled Trials (CENTRAL)
and review-specific searches of additional databases. Reports
of trials are also sourced from international trials registries,
drug companies, the handsearching of key journals, conference
proceedings and other (non-Cochrane) systematic reviews and
meta-analyses. Details of CCMD's core search strategies (used to
identify RCTs) can be found on the Group's website with an example
of the core MEDLINE search displayed in Appendix 2.
In 2016 the Group’s Specialised Register (CCMD-CTR) became out of
date with the Editorial Group’s move from Bristol to York.
Electronic searches
The Cochrane Common Mental Disorders' Information Specialist
will conduct searches on the following bibliographic databases
using relevant subject headings (controlled vocabularies) and
search syntax, appropriate to each resource.
• CCMD Specialised Register (CCMD-CTR) all available years;
• Cochrane Central Register of Controlled Trials (CENTRAL;
current year and issue);
• Ovid MEDLINE databases (1946 onwards) search strategy listed
in Appendix 3;
• Ovid Embase (1974 onwards);
• Ovid PsycINFO (all available years).
We will not apply any restrictions on date, language or publication
status to the searches.
We will search international trials registries via the World Health
Organization's trials portal (ICTRP) and ClinicalTrials.gov to identify
unpublished or ongoing trials.
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Searching other resources
Grey literature
We will search the grey literature for dissertations and
theses, clinical guidelines and regulatory agency reports (where
appropriate).
• Open Grey (www.opengrey.eu/);
• ProQuest Dissertations & Theses Global (www.proquest.com/);
• DART-Europe E-theses Portal (www.dart-europe.eu/);
• EThOS - the British Libraries e-theses online service
(ethos.bl.uk/);
• Open Access Theses and Dissertations (oatd.org).
Reference lists
We will check the reference lists of all included trials and relevant
systematic reviews to identify additional trials missed from the
original electronic searches (for example unpublished or in-press
citations).
Correspondence
We will contact trial authors and subject experts for information on
unpublished or ongoing trials, or to request additional trial data.
Data collection and analysis
Selection of studies
Two review authors (EVL, KA) will independently screen titles and
abstracts for inclusion of all the potential trials we identify as
a result of the search and code them as 'retrieve' (eligible or
potentially eligible/unclear) or 'do not retrieve'. We will retrieve
the full-text trial reports and publications, and two review authors
(EVL, KA) will independently screen the full text, identify trials
for inclusion, and identify and record reasons for exclusion of
the ineligible trials. We will resolve any disagreement through
discussion or, if required, we will consult  a third review author
(MVD). We will identify and exclude duplicate records and we will
collate multiple reports that relate to the same trial so that each
trial rather than each report is the unit of interest in the review. We
will record the selection process in suFicient detail to complete a
PRISMA flow diagram (Moher 2009), and Characteristics of included
and excluded studies tables.
Data extraction and management
We will use a data collection form to extract trial characteristics
and outcome data, which we will pilot on at least one trial in the
review. Two review authors (EVL, KA) will independently extract
trial characteristics and outcome data from included trials. We will
extract the following trial characteristics.
• Methods: trial design, total duration of trial, details of any 'run-
in' period, number of trial centres and location, trial setting,
withdrawals, and date of trial
• Participants: number, mean age, age range, gender, severity of
condition, duration of antidepressant treatment before trial,
comorbidity, setting (primary care versus outpatient psychiatric
hospital versus nursing home), diagnostic criteria, inclusion
criteria, and exclusion criteria
• Interventions: intervention inclusive mode of discontinuation
(gradually or abruptly), comparison, concomitant treatment
(psychological treatment, medications)
• Outcomes: primary and secondary outcomes specified and
collected, and time points reported
• Notes: funding for trial, and notable conflicts of interest of trial
authors
We will note in the 'Characteristics of included studies' table if
trials did not report outcome data in a usable way. We will resolve
disagreements by consensus or by involving a third review author
(MVD). One review author (EVL) will transfer data into the Review
Manager 5 file (Review Manager 2014). We will double-check that
data are entered correctly by comparing the data presented in the
systematic review with the trial reports. A second review author
(KA) will spot-check trial characteristics for accuracy against the
trial report.
Main planned comparisons
• Abrupt discontinuation versus continued antidepressant use or
usual care
• Tapering versus continued antidepressant use or usual care
• Combined intervention (with high-intensity psychological
treatment) versus continued antidepressant use or usual care
• Combined intervention (with low-intensity psychosocial
treatment) versus continued antidepressant use or usual care
• Discontinuation with pharmacological treatment versus
continued antidepressant use or usual care
Co-interventions of any kind of non-pharmacology treatment for
discontinuation in the intervention and the control group are
allowed.
Assessment of risk of bias in included studies
Two review authors (EVL, KA) will independently assess risk of bias
for each trial using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions  (Higgins 2017). We will
resolve any disagreements by discussion or by involving another
review author (MVD). We will assess the risk of bias according to the
following domains.
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective outcome reporting
• Other bias
We will judge each potential source of bias as high, low or unclear
and provide a supporting quotation from the trial report together
with a justification for our judgment in the 'Risk of bias' table.
We will summarise the 'Risk of bias' judgements across diFerent
trials for each of the domains listed. We will consider blinding
separately for diFerent key outcomes where necessary (e.g. for
unblinded outcome assessment, risk of bias for all-cause mortality
may be very diFerent than for a participant-reported pain scale).
Where information on risk of bias relates to unpublished data or
correspondence with the trial authors, we will note this in the 'Risk
of bias' table.
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When considering treatment eFects, we will take into account the
risk of bias for the trials that contribute to that outcome.
Measures of treatment e8ect
Dichotomous data
We will analyse dichotomous data as proportions and express the
pooled estimates as odds ratios (OR) with 95% confidence intervals
(95% CI).
Continuous data
For continuous data we will enter data from various scales,
questionnaires and other clinical measures. We will analyse
continuous data as means and express the pooled estimate as
a mean diFerence (MD), if the trials used the same scale, or
standardised mean diFerence (SMD), if they used diFerent scales
to measure the same outcome, with a standard deviation (SD). We
will calculate a 95% CI for each estimate. We will analyse ‘time to
relapse’ as hazard ratios where the data are provided as a time to
event.
Unit of analysis issues
Participants in RCTs are the unit of analysis.
Cluster-randomised trials
We plan to incorporate results from cluster-RCTs into the review
using generic inverse variance methods (Deeks 2017). With cluster-
RCTs, it is important to ensure that data were analysed with
consideration of their clustered nature. We will extract the
intraclass correlation coeFicient (ICC) for each trial. We will adjust
for the clustering eFect by dividing the clusters by a 'design eFect'.
We will calculate this using the number of participants or the mean
size per cluster and the intraclass correlation coeFicient (ICC). If the
ICCs are not reported, we plan to request them from trial authors. If
these data are not available, we plan to use estimates from similar
trials to 'correct' data for clustering when this has not been done
(Deeks 2017).
Trials with multiple treatment groups
For trials with two or more active treatment arms, we will undertake
the following approach according to whether the outcome is
continuous or dichotomous. For a continuous outcome: we will
pool means, SDs, and the number of participants for each active
treatment group across treatment arms as a function of the number
of participants in each arm for comparison against the control
group (Deeks 2017). For a dichotomous outcome: we plan to
combine active treatment groups into a single arm for comparison
against the control group (in terms of numbers of people with
events and sample sizes) or to split the control group equally (Deeks
2017).
Dealing with missing data
Where possible, we will carry out an intention-to-treat (ITT) analysis
for all outcomes. We will contact investigators or trial sponsors in
order to verify key trial characteristics and obtain missing numerical
outcome data where possible (e.g. when a trial is identified as
abstract only). We will document all correspondence with trial
authors and report which trial authors responded in the full review.
We will calculate the percentage lost to follow-up in each group and
report this information. We will not make any assumptions about
loss to follow-up for dichotomous or continuous data. We will then
conduct a complete-case analysis and include in the analysis only
participants with a recorded outcome.
Assessment of heterogeneity
We will assess heterogeneity in two ways. First, we will explore the
presence of heterogeneity at face value by comparing population
groups, interventions or outcomes across trials. In the case of clear
face value heterogeneity, we will not pool the results. We will only
perform meta-analysis when trials are suFiciently homogeneous in
terms of participants, interventions, and outcomes. If there is no
obvious clinical heterogeneity we will use statistical tests such as
the Chi2 test and the I2 statistic (Higgins 2003), to determine the
presence and level of statistical heterogeneity for each outcome.
We will interpret the I2 statistic, accompanied by a statistically
significant Chi2 test as follows: 0% to 40% might not be important,
30% to 60% may represent moderate heterogeneity, 50% to
90% may represent substantial heterogeneity, and 75% to 100%
considerable heterogeneity (Deeks 2017).
Assessment of reporting biases
To minimise risk of publication bias, we will perform a
comprehensive search in multiple databases, including searching
for unpublished trials. We will investigate potential publication bias
by using a funnel plot if at least 10 trials meet the inclusion criteria
of the review.
Data synthesis
We will pool data from diFerent trials if we consider that the trials
are suFiciently similar. If a Chi2 test and I2 statistic indicate there
is no important heterogeneity, we will use a fixed-eFect model
for meta-analysis. If there is evidence of important heterogeneity
between trials, we will either pool only homogeneous trials, or
use a random-eFects model (Deeks 2017). When a meta-analysis
is not possible (e.g. owing to insuFicient data or substantial
heterogeneity), we will describe the results for individual trials
separately. We will discuss the heterogeneity of the included trials
and the external validity of the review in the section 'Overall
completeness and applicability of evidence'. We will use hazard
ratios to compare the outcome time to relapse between trials.
We will also use a random-eFects model to pool trial data
reported as time-to-event rates. We will calculate the primary
outcomes (i.e. successful and unsuccessful discontinuation rate,
relapse rate, discontinuation symptoms and adverse events due to
antidepressant use) as the proportion of all participants included
in both intervention groups (ITT) and as the proportion of all
participants with the intention to attempt discontinuation of
unnecessary antidepressants (per-protocol analysis).
Subgroup analysis and investigation of heterogeneity
We will investigate heterogeneity by conducting prespecified
subgroup analyses and compare subgroups using the formal test
for subgroup diFerences for primary outcomes
• Age group: younger than 65 years versus 65 years and older.
Harms of antidepressants and a higher risk for drug-drug
interactions are more common in older people with oOen
existing polypharmacy and co-morbidities due to changed
pharmacokinetics and pharmacodynamics.
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• Setting: primary care versus outpatient specialist clinics.
Primary care can be primary care consultation and nursing
home. The setting could influence the eFect due to the severity
of disease treated with antidepressants in outpatient specialist
clinics.
• Indication of antidepressant drugs: anxiety versus depression.
The original indication could influence the success of
discontinuation due to the diFerences in clinical presentation
and management of anxiety and depression.
• Type of antidepressants: TCA versus SSRI. Type of
antidepressant could influence the eFect due to the higher risk
of adverse events with TCAs because of their anticholinergic
properties. TCAs have a comparable eFectiveness as SSRIs with
a less favourable risk–benefit ratio (NICE 2016).
• Duration of antidepressant treatment: one year or longer versus
less than one year. The recommended duration of continuation
treatment aOer remission varies from four months to 12 months
in depression guidelines. The duration of use could influence
the success of discontinuation due to the dependence on
medication (Kendrick 2015)
Sensitivity analysis
We will carry out sensitivity analysis to assess the impact on
the eFect estimate of trials with a high risk of bias. We will test
the impact of including trials assessed as high risk of bias by
removing trials with at least one high risk rating in the 'Risk of bias'
assessment.
'Summary of findings' table
We will include a ’Summary of findings’ table, prepared using
GRADEpro GDT, for seven outcomes:
1. Successful discontinuation rate
2. Relapse rate
3. Discontinuation symptoms
4. Depressive and anxiety symptoms
5. Adverse events due to antidepressant use
6. Quality of life
7. Social and occupational functioning
Two review authors (EVL, KA) will use the GRADE approach
independently to assess evidence certainty for all outcomes.
We will assess evidence as high-, moderate-, low-, or
very low-certainty, depending on the seriousness of concern
about risk of bias, imprecision, inconsistency, indirectness,
and publication bias. We will present the comparisons
'Tapering versus continued antidepressant use or usual care' ,
'Combined intervention (high-intensity psychological treatment)
versus continued antidepressant use or usual care' and
'Combined intervention (low-intensity psychosocial treatment)
versus continued antidepressant use or usual care' in the
'Summary of findings' table. For each outcome in the 'Summary of
findings’ table we will present a summary of the available data, the
magnitude of the eFect size, and the certainty of the evidence. We
will justify all decisions to downgrade the certainty of evidence in
the footnotes of the 'Summary of findings' table.
We will prioritise outcomes over the medium term (from four weeks
to six months) and long term (follow-up 6 months or more).
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A D D I T I O N A L   T A B L E S
 
Classes of antidepressants Examples
A. Major classes of antidepressants  
Selective serotonin reuptake inhibitors (SSRIs) Citalopram, escitalopram, fluoxetine, fluvoxam-
ine, paroxetine, sertraline
Serotonin-noradrenaline reuptake inhibitors (SNRIs) Duloxetine, venlafaxine, desvenlafaxine, mil-
nacipran, levomilnacipran
Noradrenaline reuptake inhibitors (NARIs) Reboxetine
Tricyclic antidepressants (TCAs) and related Amitriptyline, clomipramine, dosulepine, dox-
epine, imipramine, nortriptyline, maprotiline
Noradrenaline-dopamine reuptake inhibitors (NDRIs) Bupropion
Table 1.   Di8erent classes of antidepressants 
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Monoamine oxidase inhibitors (MAOIs) Fenelzine, moclobemide, tranylpromine
B. Other drugs used to treat depression
Melatonergic antidepressants Agomelatine
Noradrenergic and specific serotonergic antidepressant (NaSSA) and related
drugs
Mirtazepine, mianserin
Serotonin antagonist and reuptake inhibitors (SARIs) Trazodone
Multimodal serotonin reuptake inhibitor and receptor blocker Vortioxetine, vilazodone
Hypericum perforatum (St John's Wort)  
Table 1.   Di8erent classes of antidepressants  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Abbreviations
 
BAI Beck Anxiety Scale
BDI Beck Depression Inventory
BSI Brief Symptom Inventory
CESD Centre for Epidemiological Studies Depression Scale
CGI Clinical Global Impression
IDS Inventory of Depressive Symptomatology
DESS Discontinuation-Emergent Signs and Symptoms Scale
DSM-V Diagnostic and Statistical Manual of Mental Disorders
GAD-7 General Anxiety Disorder 7-item
GAFS Global Assessment of Functioning Score
HAM-A Hamilton Anxiety Scale
HDRS Hamilton Depression Rating Scale
LSAS Liebowitz Social Anxiety Scale
MADRS Montgomery-Åsberg Depression Rating Scale
NNTB Number needed to treat for an additional beneficial outcome
NNTH Number needed to treat for an additional harmful outcome
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OFS Occupational Functioning Scale
PAS Panic and Agoraphobia Scale
PHQ Patient Health Questionnaire
QALY Quality Adjusted Life Years
SF-12 Short Form 36 Items Health Survey
SF-36 Short Form 12 items Health Survey




Appendix 2. OVID Medline: Cochrane Common Mental Disorders' core search strategy used to inform the specialised
register
A weekly search alert based on condition + randomised controlled trial (RCT) filter only
The Cochrane Common Mental Disorders Controlled Trials Register (CCMD-CTR) is current to June 2016 only (when the editorial base moved
from the Univeristy of Bristol to the University of York).
1. [MeSH Headings]:
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/ or pica/ or
hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or
mood disorders/ or aFective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal aFective
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive agents/ or anxiety disorders/ or
agoraphobia/ or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic
disorders/ or stress disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/
or anxiety/ or anxiety, castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body
dysmorphic disorders/ or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ or munchausen syndrome by proxy/ or
munchausen syndrome/ or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse
control disorders/ or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual
dysfunctions, psychological/ or vaginismus/ or Anhedonia/ or AFective Symptoms/ or *Mental Disorders/
2. [Title/ Author Keywords]:
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or
mood disorder* or aFective disorder* or bipolar i or bipolar ii or (bipolar and (aFective or disorder*)) or mania or manic or cyclothymic* or
depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia
or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#ation or medical*
unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue*
or gambling or trichotillomania or vaginismus or anhedoni* or aFective symptoms or mental disorder* or mental health).ti,kf.
3. [RCT filter]:
(controlled clinical trial.pt. or randomized controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random* adj3
(administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or place*
or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or study or
studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or clinical trial, phase
iii/ or clinical trial, phase iv/ or randomized controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental or random*)).ti,ab. or
((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
4. (1 and 2 and 3)
Records were screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders. Secondary reports of RCTs were
also tagged to the appropriate study record.
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Similar weekly search alerts were also conducted on OVID EMBASE and PsycINFO, using relevant subject headings (controlled vocabularies)
and search syntax, appropriate to each resource.
A quarterly search of the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted c/o the Cochrane Register of Studies
Online (CRSO).
Appendix 3. Other database searches
We will conduct a separate search of Ovid MEDLINE, tailored to this review.
We will translate the MEDLINE search across to the other bibliographic databases using relevant subject headings (controlled vocabularies)
and search syntax, appropriate to each resource.
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 onwards>
Search Strategy (compiled April 16, 2019):
-------------------------------------------------------------------------------
1 ((deprescrib* or de prescrib* or deprescrip* or de prescrip* or cease or cessation* or discontinu* or dropout or drop out or interrupt or
interruption* or interrupting or taper* or reduce or drug holiday or (stop* adj (taking or using)) or stopping or withdraw* or withhold* or
terminat*) adj4 (antidepress* or anti-depress* or ADM or mADM or psychotropic* or SSRI* or SNRI* or MAOI* or TCA* or tricyclic* or NARI
or NARIs or NDIR* or SARI or SARIs or NaSSA* or ((serotonin or monoamine oxidase or MAO) adj2 inhibitor*))).ti,ab,kf. (1904)
2 deprescriptions/ (204)
3 Inappropriate Prescribing/ (2571)
4 Withholding Treatment/ (11101)
5 (deprescrib* or de prescrib* or deprescrip* or de prescrip*).ti,ab,kf. (558)
6 (stop using or stop taking or stopping treatment).ti,ab,kf. (1946)
7 (cease or cessation* or discontinu* or dropout or drop out or interrupt or interuption* or interrupting or taper* or reduce or drug holiday
or stop or stopping or withdraw* or withhold* or terminat*).ti,kf,hw. (158349)
8 ((long term or longterm) adj3 (cease or cessation* or discontinu* or dropout or drop out or interrupt or interuption* or interrupting or
taper* or reduce or drug holiday or stop or stopping or withdraw* or withhold* or terminat*)).ab. (3275)
9 2 or 3 or 4 or 5 or 6 or 7 or 8 (165117)
10 exp Antidepressive Agents/ (144038)
11 exp Neurotransmitter Uptake Inhibitors/ (142539)
12 exp Monoamine Oxidase Inhibitors/ (21319)
13 (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or noradrenaline or nor epinephrine or nor adrenaline
or neurotransmitt* or dopamine*) adj3 (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI*
or SNRI* or MAOI* or ((serotonin or monoamine oxidase or MAO) adj2 inhibit*) or TCA* or tricyclic* or NARI or NARIs or NDIR* or SARI or
SARIs or NaSSA*).ti,kf,hw. (119809)
14 (Agomelatine or Alnespirone or Amoxapine or Amersergide or Amfebutamone or Amiflamine or Amineptine or Amitriptylin* or
Amitriptylinoxide or Amoxapine or Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine or Binospirone or
Brofaromine or Bupropion or Butriptylin*or Chlopoxiten or Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram
or Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine or Clorgyline or Clovoxamine or Dapoxetine or Deanol or
Dibenzepin or Demexiptilin* or Deprenyl or Desipramine or Desvenlafaxine or Dibenzepin or Dimetacrin* or Dosulepin* or Dothiepin or
Doxepin*or Duloxetine or DVS 233 or Enilospirone or Eptapirone or Escitalopram or Etoperidone or Femoxetine or Fenelzine or Fluotracen
or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine).ti,kf,hw. (40793)
15 (Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or
Imipraminoxide or Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or Lu AA21004 or Vortioxetine or Lu AA24530
or LY2216684 or Maprotiline or Medifoxamine or Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or
Nortriptyline or Noxiptilin*).ti,kf,hw. (72558)
16 (Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezin* or Pirandamine or Piribedil or Pirlindole or
Pivagabine or Pizotyline or Propizepine or Protriptylin* or Pertofrane or Quinupramine or Quipazine or Reboxetine or Ritanserin or
Rolipram or Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Tandospirone or Teniloxine or Tetrindole or Thiazesim or
Thozalinone or Tianeptin* or Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5 Hydroxytryptophan or 5 HT or Tryptophan
or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Vortioxetine or Zalospirone or Zimeldine).ti,kf,hw. (75794)
17 or/10-16 (326547)
18 9 and 17 (6834)
19 1 or 18 (8100)
20 controlled clinical trial.pt. (93029)
21 randomized controlled trial.pt. (480058)
22 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kf. (579180)
23 (RCT or "at random" or (random* adj3 (administ* or allocat* or assign* or class* or cluster or control* or determine* or divide* or division
or distribut* or expose* or fashion or number* or place* or pragmatic or quasi or recruit* or split or subsitut* or treat*))).ti,ab,kf. (488976)
Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults (Protocol)













27 (control* and (trial or study or group*) and (placebo or waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,kf,hw. (186303)
28 ((single or double or triple or treble) adj2 (blind* or mask* or dummy)).ti,ab,kf. (163907)
29 double-blind method/ or random allocation/ or single-blind method/ (264679)
30 or/20-29 (2820037)
31 exp animals/ not humans.sh. (4569557)
32 30 not 31 (2381687)
33 19 and 32 (1996)
34 *Depression/ (65673)
35 *Depressive Disorder/ (51970)
36 *Depressive Disorder, Major/ (22776)
37 drug therapy.fs. (2099633)
38 34 or 35 or 36 (133590)
39 37 and 38 (32923)
40 9 and 32 and 39 (217)
41 33 or 40 (2041)
42 (smoking or tobacco or nicotine or alcohol or substance).ti. or smoking cessation.ab,kf,hw. (238392)
43 41 not 42 (1298)
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